[Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)]. / Aktuelle Entwicklungen in der Therapielandschaft des metastasierten hormonsensitiven Prostatakarzinoms (mHSPC).

ABSTRACT

Despite major developments in the therapy of advanced prostate cancer over the past decade, there was still an unmet medical need for efficacious and safe therapies suitable for a wide patient population of patients with metastatic hormone-sensitive disease.Since its label extension for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) at the beginning of 2020, apalutamide in combination with androgen deprivation therapy (ADT) has filled this gap 1. The novel androgen receptor inhibitor showed good efficacy and safety in comparison with placebo in the pivotal study TITAN while maintaining quality of life - the study included patients irrespective of risk, disease volume, or time of diagnosis 2.